2020: A Watershed Year for Chinese Biotech
2020 will certainly go down in history as a watershed year for the global community, as a new strain of coronavirus – later named SARS-CoV-19 – originating from the city…
Address: Room 301,E unit, 3rd Building,Helicon Garden (Hongjialiyuan), Haidian District,Beijing 100088,China
Tel: (86-10)82050626
Formed in May 1988, the purpose of CNMA is to promote and raise the level of research, production and sales management of the Chinese OTC industry in compliance with social ethics and the relevant laws, regulations and policies.
CNMA represents the members’interests and submits policy advices to the concerned government departments on drugs’ classification, OTC research, production and sale.
CNMA also provides the members with consulting, training and information services to promote OTC technology, enhance OTC quality and ensure the consumers’ safety in using OTC products.
Another key role is to raise the knowledge and awareness about self-medication and OTC products. CNMA also organizes different activities to strengthen cooperation and contacts with international organizations, OTC associations and enterprises.
Industry Regulation and Coordination, Education
2020 will certainly go down in history as a watershed year for the global community, as a new strain of coronavirus – later named SARS-CoV-19 – originating from the city…
A roundup of the latest news from Chinese biotechs, including a bumper IPO for Legend Biotech, a USD two million tie-up between Roche and Innovent Biologics, and a new Alphamab-Sanofi…
Johnson & Johnson’s network of healthcare innovation incubators, JLABS, opened its doors in Shanghai in June 2019 and now stands as the largest such institution of 13 globally. JLABS @…
Pierre A Morgon, SVP International Business for CanSino Biotechnology (CanSinoBIO) – a Chinese vaccine biotech developing one of the frontrunner COVID-19 vaccine candidates – shares how his extensive international career…
Highly potent neutralizing antibodies may be the key to laying a foundation for COVID-19 treatment, according to a Chinese research team led by Peking University. The worldwide race against…
A roundup of some of the top stories in China’s healthcare and life sciences industry, including challenges for Chinese biotechs in the post-pandemic era, why the country needs a biosecurity…
Dr Joan Shen, CEO of I-Mab Biopharma, shares her impressive career journey across companies like Pfizer, Janssen and Jiangsu Hengrui, before joining I-Mab, as well as introducing what I-Mab 2.0…
A roundup of the latest news in Chinese pharma, including a US IPO for Burning Rock Biotech, positive news on CanSino’s COVID-19 vaccine trials, and WuXi Biologics’s first US facility.…
Dr Sharon Chan, head of JLABS @ Shanghai – the first JLABS presence in Asia-Pacific as well as the largest globally – shares how Johnson & Johnson is investing in…
Alphamab Oncology and I-Mab Biopharma, two of China’s fastest-growing biotech firms, both bolstered by recent successful IPOs, are increasingly adapting their portfolio strategies to launch products on the large but…
Established in December 2012, in less than a decade, Chinese biotech Junshi Biosciences has already transformed itself into a publicly-listed commercial company with a successful USD 450 million IPO on…
PharmaBoardroom caught up with Alphamab Oncology’s founder, chairman and CEO Dr Xu Ting again 16 months after our last interview to hear about their successful HKEX IPO in December 2019,…
See our Cookie Privacy Policy Here
